WebDoctor Encyclopedia

Article

Allogeneic Stem Cell Transplant

What is an allogeneic stem cell transplant?

An allogeneic stem cell transplant replaces a person’s diseased or damaged blood-forming system with healthy stem cells from a donor. The word allogeneic means “from another person”. The donor may be a brother or sister, an unrelated volunteer found through a registry, a half-matched family member such as a parent or child, or blood from a baby’s umbilical cord.

Blood stem cells live in the bone marrow and make all the red cells, white cells and platelets the body needs. Before the transplant, the patient receives chemotherapy, sometimes with radiotherapy, called conditioning. The donor cells are then given through a drip, much like a blood transfusion. They travel to the bone marrow, settle in and begin making new blood.

What makes this transplant special is that the new immune system comes from the donor. Donor immune cells can recognise and attack leukaemia cells that survived conditioning. This is called the graft-versus-leukaemia (or graft-versus-tumour) effect, and it is one of the main reasons the treatment can cure blood cancers that chemotherapy alone cannot.

The same donor immune cells can also attack healthy tissues, causing graft-versus-host disease (GVHD). Balancing the benefits against this and other risks is at the heart of every transplant decision.

A brief history

The first successful bone marrow transplants between siblings were performed in the late 1960s and 1970s, building on decades of work on tissue typing. Large international donor registries grew in the 1980s and 1990s, making unrelated donors widely available. Gentler “reduced-intensity” conditioning, introduced around the turn of the century, opened up transplant to older people. More recently, new ways of preventing GVHD have made half-matched family donors a realistic option for most patients.

1. Key facts at a glance

Feature Details
Type of treatment Stem cell transplant using cells from a donor
Main uses Acute leukaemias, myelodysplastic syndromes, myelofibrosis and some lymphomas
Donor types Matched sibling, matched unrelated, half-matched (haploidentical) family member, umbilical cord blood
How cells are given Drip into a central line after conditioning chemotherapy, with or without radiotherapy
Hospital stay Usually 3-6 weeks
Recovery Close follow-up for at least 100 days; full recovery often takes 1-2 years
Main risks Infection, graft-versus-host disease, organ damage, graft failure, relapse

2. How it works

Three key steps

Step Purpose
Conditioning Destroys remaining cancer cells and suppresses the patient’s immune system so donor cells are not rejected
Infusion of donor cells Provides a new source of blood and immune cells
Engraftment Donor cells settle in the marrow and start making blood, usually within 2-4 weeks

Types of conditioning

Type Description Typical patient
Myeloablative High doses that wipe out the bone marrow completely Younger, fitter people
Reduced-intensity Lower doses that rely more on the donor immune effect Older people or those with other health problems
Non-myeloablative Very low doses Selected older or frailer people

Sources of stem cells

Source How it is collected Features
Peripheral blood Donor has growth factor injections, then cells are collected from the bloodstream by a machine Most common; faster engraftment
Bone marrow Taken from the donor’s hip bones under anaesthetic Lower risk of chronic GVHD
Umbilical cord blood Stored from a baby’s cord after birth Needs less strict matching; slower engraftment

A large trial with unrelated donors found similar two-year survival with blood or marrow stem cells. Blood stem cells lowered the risk of the graft failing, while marrow was linked to less chronic GVHD (Anasetti et al., 2012).

Tissue matching

Doctors match donors using HLA typing, a blood test of proteins on the surface of cells that the immune system uses to tell “self” from “non-self”. A brother or sister has a 1 in 4 chance of being a full match. When no sibling matches, registries of millions of volunteers are searched. People from ethnic groups that are under-represented on registries may find a full match harder to find, which is one reason haploidentical and cord blood transplants are so valuable.

3. Who it is for

Conditions treated

Condition When transplant is considered
Acute myeloid leukaemia Intermediate or high-risk disease in first remission, or after relapse
Acute lymphoblastic leukaemia High-risk features, persisting disease or relapse
Myelodysplastic syndromes Higher-risk disease in suitable patients; the only treatment that can cure it
Myeloproliferative neoplasms Higher-risk myelofibrosis
Chronic myelomonocytic leukaemia Higher-risk disease in fit patients
Chronic myeloid leukaemia Advanced phase or resistance to several kinase inhibitors
Mixed phenotype acute leukaemia Often recommended in first remission
Juvenile myelomonocytic leukaemia Main curative treatment for most children
Hodgkin lymphoma Relapse after an autologous transplant
T-cell prolymphocytic leukaemia To consolidate a first response in fit patients

Weighing up the decision

Transplant is a major treatment, so doctors compare the expected benefit with the risks for each person. The European Group for Blood and Marrow Transplantation risk score combines five factors: the patient’s age, the stage of disease, the time from diagnosis, the donor type and the sex combination of donor and recipient (Gratwohl, 2012). Fitness, other illnesses and the patient’s own wishes are also taken into account.

4. Before treatment

Step Why it is done
HLA typing Patient and possible family donors are tested
Donor search Registries searched if no family match
Disease assessment Bone marrow test to confirm remission
Organ function tests Heart scan, breathing tests, kidney and liver function
Dental check Treats sources of infection before immunity drops
Infection screening Checks for viruses such as CMV, hepatitis and HIV
Fertility discussion Conditioning often causes infertility; sperm or egg storage may be possible
Central line A tube placed in a large vein for drips and blood tests
Carer planning A carer is usually needed for several months after discharge

5. What to expect: step by step

Step What happens
1. Admission Usually a few days before the transplant
2. Conditioning Chemotherapy, sometimes with total body irradiation, over about 2-7 days
3. Day 0 Donor cells are given through the central line over about an hour
4. Low count period For 2-4 weeks, blood counts are very low; transfusions and antibiotics are often needed
5. Engraftment White cells start to recover
6. Discharge Home or nearby accommodation when counts and eating have recovered
7. Early follow-up Clinic visits once or twice a week for the first 100 days
8. Long-term follow-up Less frequent visits for life

Medicines after transplant

Most people take medicines to prevent GVHD, such as ciclosporin or tacrolimus, often with methotrexate or other drugs. Many centres now give post-transplant cyclophosphamide, a few days after the infusion, to reduce GVHD, particularly with half-matched donors. Antiviral, antifungal and antibiotic tablets protect against infection while the new immune system develops.

6. Side effects and risks

Risk What it involves
Infection Bacterial, viral and fungal infections; reactivation of viruses such as CMV
Acute GVHD Usually in the first months; rash, diarrhoea or liver problems
Chronic GVHD Later; dry eyes and mouth, skin tightening, lung or joint problems
Mouth sores (mucositis) From conditioning; may need strong pain relief and tube feeding
Nausea, diarrhoea and hair loss From conditioning
Graft failure Donor cells do not take or are lost
Organ damage Liver, kidney, lung or heart problems
Infertility Common after myeloablative conditioning
Relapse The original disease can return
Late effects Cataracts, hormone problems, bone thinning, second cancers

Graft-versus-host disease

GVHD happens when donor immune cells attack the patient’s tissues, most often the skin, gut and liver. It is prevented with immune-suppressing medicines and treated, when it occurs, mainly with steroids. A review of acute GVHD describes how damage from conditioning triggers inflammation that activates donor T cells (Zeiser and Blazar, 2017).

For people whose GVHD does not respond to steroids, newer drugs such as ruxolitinib are now available. Mild GVHD may be linked with a stronger effect against leukaemia, so doctors aim to control it rather than eliminate every trace.

7. Results and outlook

Evidence Main finding
Randomised trial of blood vs marrow stem cells from unrelated donors (551 people) Two-year survival was about half in both groups (51% vs 46%), with less graft failure using blood stem cells and less chronic GVHD using marrow (Anasetti et al., 2012)
EBMT risk score Survival is consistently better in younger people transplanted early in their disease with a well-matched donor (Gratwohl, 2012)
Review of stem cell transplantation Describes how transplant offers cure for many blood cancers through both high-dose therapy and the donor immune effect (Copelan, 2006)

Results depend greatly on the disease, its stage, the patient’s age and fitness, and the donor. People transplanted in first remission generally do better than those transplanted with active disease. Your team can give you figures that apply to your situation.

8. Recovery and aftercare

The first 100 days

Tip Why
Stay close to the transplant centre Frequent visits and quick access if problems arise
Take every medicine as prescribed Immune-suppressing and anti-infection drugs are vital
Report fever straight away Infection can become serious quickly
Follow food safety advice Reduces the risk of food-borne infection
Avoid crowds and people who are unwell Your immune system is still weak
Check your skin, gut and eyes Early GVHD is easier to treat

Longer-term recovery

Area What to expect
Energy Tiredness can last for months; gradual exercise helps
Vaccinations Childhood vaccines are repeated, starting from several months after transplant
Work and school Many people return within 6-12 months, sometimes longer
Emotional health Anxiety and low mood are common; support is available
Survivorship clinic Screening for late effects such as hormone, bone, heart and skin problems

Relapse after transplant

If the disease returns, options may include stopping immune-suppressing drugs to boost the donor effect, an infusion of extra donor immune cells (donor lymphocyte infusion), targeted drugs, or occasionally a second transplant.

Caring for someone after transplant

Carers play a central role, especially in the first few months. Tasks can include giving medicines, spotting warning signs, preparing safe food and travelling to appointments. Transplant teams usually run carer education sessions, and it is important for carers to look after their own health and seek support.

Being a donor

Donors are carefully checked to make sure donation is safe for them. Blood stem cell donation feels similar to giving blood but takes several hours, after a few days of growth factor injections that can cause bone aches. Marrow donation needs a short anaesthetic and causes soreness in the hips for a few days. Most donors recover quickly.

9. Alternatives

Alternative When it is considered
Autologous stem cell transplant Uses the patient’s own cells; for myeloma and some lymphomas, but has no donor immune effect
CAR-T cell therapy Some relapsed lymphomas and B-cell ALL
Chemotherapy alone Lower-risk leukaemias
Targeted drugs or low-intensity treatment People not fit for transplant
Clinical trials New conditioning and GVHD prevention approaches

10. Frequently asked questions

Question Answer
Is the transplant an operation? No, the cells are given through a drip
Will my blood group change? It may change to the donor’s blood group
Can I meet my donor? Rules vary by country; contact may be possible after a set time
What if no matched donor is found? Half-matched family donors or cord blood are often used
Will I be able to have children? Fertility is often affected; ask about storing sperm or eggs beforehand
When can I drive or travel? Usually after several months; check with your team
How long until my immune system recovers? Often 1-2 years

11. Questions to ask your care team

  • Why do you recommend a transplant for me, and what are the alternatives?
  • What kind of donor do you plan to use?
  • What type of conditioning will I have?
  • What are my chances of cure, relapse and serious complications?
  • How long will I be in hospital, and how far from the centre can I live afterwards?
  • Who can be my carer, and what will they need to do?
  • How will my fertility be affected?

Resources

  1. Anasetti, C. et al. (2012) ‘Peripheral-blood stem cells versus bone marrow from unrelated donors’, New England Journal of Medicine, 367(16), pp. 1487-1496.
  2. Copelan, E.A. (2006) ‘Hematopoietic stem-cell transplantation’, New England Journal of Medicine, 354(17), pp. 1813-1826.
  3. Gratwohl, A. (2012) ‘The EBMT risk score’, Bone Marrow Transplantation, 47(6), pp. 749-756.
  4. Zeiser, R. and Blazar, B.R. (2017) ‘Acute graft-versus-host disease – biologic process, prevention, and therapy’, New England Journal of Medicine, 377(22), pp. 2167-2179.
  5. National Cancer Institute (2026) Stem Cell and Bone Marrow Transplants for Cancer. Available at: https://www.cancer.gov/about-cancer/treatment/types/stem-cell-transplant (Accessed: October 2026).
  6. National Cancer Institute (2026) Acute Myeloid Leukemia Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/leukemia/hp/adult-aml-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.